What are real world exclusion criteria for the use of lenvatinib + pembrolizumab for advanced endometrial cancer?
Are there specific clinical or social scenarios that would preclude the use of this treatment?
Community PollStarted
What patient factors would make you more likely (than chemotherapy) to use lenvatinib + pembrolizumab for advanced endometrial cancer?
38 physicians have voted
Join Mednetto vote and see how they answered.
2 Answers
Mednet MemberInvited Expert
Gynecologic Oncology · UCLA David Geffen School of Medicine/UCLA Medical Center
Answered on
- Poorly controlled Hypertension
- Active flare of autoimmune disease
- On immunosuppressant therapies
Join for free or sign in to see the full answer
Mednet Member
Gynecologic Oncology · University of Texas Southwestern Medical Center
Answered on
Patients with active auto-immune disease or uncontrolled hypertension should give one pause.
Join for free or sign in to see the full answer